医学
干细胞
诱导多能干细胞
胚胎干细胞
祖细胞
间充质干细胞
细胞疗法
间质细胞
移植
肝病
细胞生物学
癌症研究
再生医学
生物信息学
免疫学
干细胞疗法
病理
生物
外科
内科学
基因
生物化学
作者
Alexander Boyd,Philip N. Newsome,Wei-Yu Lu
标识
DOI:10.1080/17474124.2019.1618186
摘要
Introduction: Liver disease is an increasing cause of worldwide mortality, and currently the only curative treatment for end-stage liver disease is whole organ allograft transplantation. Whilst this is an effective treatment, there is a shortage of suitable grafts and consequently some patients die whilst on the waiting list. Cell therapy provides an alternative treatment to increase liver function and potentially ameliorate fibrosis.Areas covered: In this review, we discuss the different cellular sources for therapy investigated to date in humans including mature hepatocytes, hematopoietic stem cells, mesenchymal stromal cells and hepatic progenitor cells. Cells investigated in animals include embryonic stem cells, induced pluripotent stem cells and directly reprogrammed cells. We then appraise the experience and evidence base underlying each cell type.Expert opinion: We discuss how this field may evolve in the years to come focusing on opportunities to enhance the intrinsic regenerative response with therapeutic targets and cell therapies. Growing expertise in tissue engineering will likely lead to increasingly complex bio-reactors and bio-artificial livers, which open a further avenue to restore liver function and delay or prevent the need for transplantation.
科研通智能强力驱动
Strongly Powered by AbleSci AI